Last reviewed · How we verify
NCT06175403
A Study of Niacin Regulation
EARLY_PHASE1 trial testing Niacin in Excessive Weight Gain in 32 participants. Currently enrolling.
31 May 2027
Quick facts
| Lead sponsor | Mayo Clinic |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 32 |
| Start date | 1 January 2024 |
| Primary completion | 31 May 2027 |
| Estimated completion | 31 May 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Niacin (NIACIN) — full drug profile →
Conditions studied
- Excessive Weight Gain — all drugs for Excessive Weight Gain →
Sponsor
Mayo Clinic
Who can join
Adults 18 to 65, any sex, with Excessive Weight Gain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Adults who gain most of their excess weight in the abdominal area typically do not respond to things that "turn off" fat cells the same way as lean people. The researchers are trying to understand why fat tissue responds differently in people with different body types.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06175403
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Niacin
Trials testing the same drug.
- NCT06858332 — Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia · recruiting
- NCT06200155 — Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy · Phase 2 · recruiting
- NCT04424225 — Visual Surround Suppression and Perceptual Expectation Under Psilocybin · Phase 1 · terminated
- NCT04703361 — Effects of Ketones and Niacin in Heart Failure Patients · Phase 2 · completed
- NCT04630964 — The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density · Phase 2 · completed
Other Mayo Clinic trials
Trials by the same sponsor.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
- NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
- NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06175403 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06175403.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing